Ask AI
Breast Cancer Discoveries From ASCO 2025

CE / CME

Bridging Breast Cancer Discoveries to Practice—CCO’s Independent Conference Highlights From the 2025 ASCO Annual Meeting

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

ABIM MOC: maximum of 0.75 Medical Knowledge MOC point

Released: July 15, 2025

Expiration: January 14, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

How likely would you be to consider T-DXd + pertuzumab as first-line therapy for patients with advanced HER2+ breast cancer should this combination be approved based on data from the phase III DESTINY-Breast09 trial?

2.

Which of the following therapies was shown to significantly prolong median PFS in patients with advanced HR+/HER2- breast cancer developing an ESR1 mutation while receiving first-line therapy with an AI + CDK4/6 inhibitor in the phase III SERENA-6 trial?

3.

Which of the following findings was reported from the phase III ASCENT-04 trial that compared first-line sacituzumab govitecan + pembrolizumab vs chemotherapy + pembrolizumab in patients with advanced PD-L1–positive TNBC?